Salmeterol injection - Evofem Biosciences

Drug Profile

Salmeterol injection - Evofem Biosciences

Alternative Names: LIPO-202; Salmeterol xinafoate - Evofem Biosciences

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lithera
  • Developer Evofem Biosciences
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Subcutaneous fat disorders

Most Recent Events

  • 17 Jan 2018 Evofem Biosciences merged with Neothetics to form Evofem Biosciences
  • 08 Sep 2017 Salmeterol injection is still in phase III development for Subcutaneous fat disorders in USA (Neothetics pipeline, September 2017)
  • 02 Jun 2017 Neothetics completes the LIPO-202-CL-31 phase II trial for Subcutaneous fat disorders in USA (SC) (NCT03005717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top